Impact of Cardiac Implantable Electronic Device Infection

Supplemental Digital Content is available in the text. Background: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. Methods: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. Results: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P<0.001), an effect that sustained beyond 12 months (hazard ratio through all follow-up, 2.30 [95% CI, 1.29–4.07]; P=0.004). Quality of life was reduced (P=0.004) and did not normalize for 6 months. Disruptions in CIED therapy were experienced in 36% of infections for a median duration of 184 days. Mean costs were $55 547±$45 802 for the hospital, $26 867±$14 893, for medicare fee for service and $57 978±$29 431 for Medicare Advantage (mean hospital margin of −$30 828±$39 757 for medicare fee for service and −$6055±$45 033 for medicare advantage). Mean out-of-pocket costs for patients were $2156±$1999 for medicare fee for service, and $1658±$1250 for medicare advantage. Conclusions: This large, prospective analysis corroborates and extends understanding of the impact of CIED infections as seen in real-world datasets. CIED infections severely impact mortality, quality of life, healthcare utilization, and cost in the US healthcare system. Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02277990

[1]  B. Wilkoff,et al.  Antibacterial Envelope to Prevent Cardiac Implantable Device Infection , 2019, The New England journal of medicine.

[2]  S. Connolly,et al.  Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. , 2018, Journal of the American College of Cardiology.

[3]  A. Greenspon,et al.  Treatment patterns, costs, and mortality among Medicare beneficiaries with CIED infection , 2018, Pacing and clinical electrophysiology : PACE.

[4]  E. Fenwick,et al.  Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection , 2018, Journal of medical economics.

[5]  M. Shoda,et al.  2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. , 2017, Heart rhythm.

[6]  B. Wilkoff,et al.  Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). , 2016, American heart journal.

[7]  A. Greenspon,et al.  Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation , 2016, Circulation. Arrhythmia and electrophysiology.

[8]  Christopher R. Ellis,et al.  Cardiac Implantable Electronic Device Infection in Patients at Risk. , 2015, Arrhythmia & electrophysiology review.

[9]  S. Saba,et al.  Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation , 2015, Journal of cardiovascular electrophysiology.

[10]  C. Henrikson,et al.  Increased Long‐Term Mortality in Patients with Cardiovascular Implantable Electronic Device Infections , 2015, Pacing and clinical electrophysiology : PACE.

[11]  Walid Saliba,et al.  Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  J. Curtis,et al.  Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry , 2014, Circulation.

[13]  C. Henrikson,et al.  Mortality and cost associated with cardiovascular implantable electronic device infections. , 2011, Archives of internal medicine.

[14]  Daniel R. Frisch,et al.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. , 2011, Journal of the American College of Cardiology.

[15]  H. Mond,et al.  The 11th World Survey of Cardiac Pacing and Implantable Cardioverter‐Defibrillators: Calendar Year 2009–A World Society of Arrhythmia's Project , 2011, Pacing and clinical electrophysiology : PACE.

[16]  M. Porter,et al.  What is value in health care? , 2010, The New England journal of medicine.

[17]  B. Wilkoff,et al.  Cardiac implantable electronic device infections: presentation, management, and patient outcomes. , 2010, Heart rhythm.

[18]  Jeffrey A. Johnson,et al.  Using Instrument-Defined Health State Transitions to Estimate Minimally Important Differences for Four Preference-Based Health-Related Quality of Life Instruments , 2010, Medical care.

[19]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[20]  G W Torrance,et al.  Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.